Ultragenyx Pharmaceutical (RARE) Amortizatization of Intangibles (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Amortizatization of Intangibles data on file, last reported at $1.0 million in Q1 2026.

• On a quarterly basis, Amortizatization of Intangibles fell 50.0% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $3.0 million, a 73.32% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, down 69.23% from the prior year.
• Amortizatization of Intangibles for Q1 2026 stood at $1.0 million, up from $516000.0 in the prior quarter.
• Over the last five years, Amortizatization of Intangibles for RARE reached as high as $4.1 million in Q4 2023 and fell as low as -$1.9 million in Q1 2022.
• Historically, Amortizatization of Intangibles has averaged $1.7 million across 5 years, with a median of $2.0 million in 2025.
• Across the five-year window, Amortizatization of Intangibles sank 101.49% in 2022 and jumped 376.68% in 2023, its largest moves.
• Year by year, Amortizatization of Intangibles stood at $1.6 million in 2022, then jumped by 148.85% to $4.1 million in 2023, then slipped by 22.5% to $3.2 million in 2024, then sank by 83.78% to $516000.0 in 2025, then surged by 93.8% to $1.0 million in 2026.
• Per Business Quant data, the three most recent Amortizatization of Intangibles figures were $1.0 million in Q1 2026, $516000.0 in Q4 2025, and $704000.0 in Q3 2025.